Standard Chem & Pharm CO., LTD. (1720.TW)
TWD 58.7
(-0.51%)
TWD 58.7
(-0.51%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.46 Billion TWD | 8.47% |
| 2022 | 1.35 Billion TWD | 13.54% |
| 2021 | 1.19 Billion TWD | -2.41% |
| 2020 | 1.21 Billion TWD | 1.7% |
| 2019 | 1.19 Billion TWD | 4.67% |
| 2018 | 1.14 Billion TWD | -5.11% |
| 2017 | 1.2 Billion TWD | 4.27% |
| 2016 | 1.15 Billion TWD | 4.19% |
| 2015 | 1.11 Billion TWD | 3.85% |
| 2014 | 1.07 Billion TWD | 3.68% |
| 2013 | 1.03 Billion TWD | -6.17% |
| 2012 | 1.1 Billion TWD | -2.18% |
| 2011 | 1.12 Billion TWD | 24.06% |
| 2010 | 906.66 Million TWD | 21.45% |
| 2009 | 746.51 Million TWD | 2.2% |
| 2008 | 730.47 Million TWD | 1.68% |
| 2007 | 718.41 Million TWD | 9.83% |
| 2006 | 654.09 Million TWD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 371.02 Million TWD | 2.6% |
| 2024 Q2 | 392.21 Million TWD | 12.1% |
| 2023 Q4 | 361.6 Million TWD | -5.82% |
| 2023 Q2 | 357.76 Million TWD | 4.44% |
| 2023 Q1 | 342.57 Million TWD | -6.52% |
| 2023 Q3 | 383.95 Million TWD | 7.32% |
| 2023 FY | 1.38 Billion TWD | 2.53% |
| 2022 Q4 | 366.47 Million TWD | 7.25% |
| 2022 FY | 1.35 Billion TWD | 13.54% |
| 2022 Q3 | 341.7 Million TWD | 3.75% |
| 2022 Q2 | 329.35 Million TWD | 4.94% |
| 2022 Q1 | 313.85 Million TWD | 4.89% |
| 2021 Q3 | 289.2 Million TWD | -6.92% |
| 2021 Q4 | 299.21 Million TWD | 3.46% |
| 2021 Q1 | 291.13 Million TWD | -10.11% |
| 2021 FY | 1.19 Billion TWD | -2.41% |
| 2021 Q2 | 310.7 Million TWD | 6.72% |
| 2020 Q1 | 301.41 Million TWD | 1.83% |
| 2020 Q4 | 323.89 Million TWD | 8.06% |
| 2020 Q3 | 299.73 Million TWD | 1.73% |
| 2020 FY | 1.21 Billion TWD | 1.7% |
| 2020 Q2 | 294.64 Million TWD | -2.25% |
| 2019 Q2 | 298.97 Million TWD | 2.52% |
| 2019 FY | 1.19 Billion TWD | 4.67% |
| 2019 Q4 | 296 Million TWD | -5.35% |
| 2019 Q3 | 312.72 Million TWD | 4.6% |
| 2019 Q1 | 291.61 Million TWD | -3.94% |
| 2018 FY | 1.14 Billion TWD | -5.11% |
| 2018 Q4 | 303.58 Million TWD | 6.63% |
| 2018 Q3 | 284.7 Million TWD | -0.29% |
| 2018 Q2 | 285.53 Million TWD | 4.97% |
| 2018 Q1 | 272 Million TWD | -11.56% |
| 2017 FY | 1.2 Billion TWD | 4.27% |
| 2017 Q1 | 293.18 Million TWD | -0.3% |
| 2017 Q4 | 307.56 Million TWD | -3.14% |
| 2017 Q3 | 317.52 Million TWD | 9.77% |
| 2017 Q2 | 289.25 Million TWD | -1.34% |
| 2016 Q2 | 302.11 Million TWD | 10.67% |
| 2016 FY | 1.15 Billion TWD | 4.19% |
| 2016 Q1 | 272.98 Million TWD | -13.93% |
| 2016 Q4 | 294.06 Million TWD | 1.77% |
| 2016 Q3 | 288.96 Million TWD | -4.35% |
| 2015 FY | 1.11 Billion TWD | 3.85% |
| 2015 Q4 | 317.16 Million TWD | 16.54% |
| 2015 Q3 | 272.13 Million TWD | 8.38% |
| 2015 Q2 | 251.1 Million TWD | -7.41% |
| 2015 Q1 | 271.19 Million TWD | -14.25% |
| 2014 Q4 | 316.27 Million TWD | 21.28% |
| 2014 FY | 1.07 Billion TWD | 3.68% |
| 2014 Q1 | 249.69 Million TWD | -17.47% |
| 2014 Q2 | 243.63 Million TWD | -2.43% |
| 2014 Q3 | 260.77 Million TWD | 7.04% |
| 2013 Q4 | 302.54 Million TWD | 24.24% |
| 2013 FY | 1.03 Billion TWD | -6.17% |
| 2013 Q3 | 243.5 Million TWD | -7.11% |
| 2013 Q1 | 224.2 Million TWD | -24.78% |
| 2013 Q2 | 262.15 Million TWD | 16.93% |
| 2012 Q3 | 264.77 Million TWD | -5.36% |
| 2012 Q4 | 298.07 Million TWD | 12.58% |
| 2012 Q2 | 279.76 Million TWD | 8.89% |
| 2012 FY | 1.1 Billion TWD | -2.18% |
| 2012 Q1 | 256.92 Million TWD | -17.79% |
| 2011 Q3 | 269.59 Million TWD | -0.39% |
| 2011 Q4 | 312.53 Million TWD | 15.93% |
| 2011 FY | 1.12 Billion TWD | 24.06% |
| 2011 Q1 | 272 Million TWD | -17.89% |
| 2011 Q2 | 270.65 Million TWD | -0.5% |
| 2010 Q1 | 179.42 Million TWD | 0.0% |
| 2010 FY | 906.66 Million TWD | 21.45% |
| 2010 Q4 | 331.25 Million TWD | 63.41% |
| 2010 Q3 | 202.71 Million TWD | 4.89% |
| 2010 Q2 | 193.26 Million TWD | 7.71% |
| 2009 FY | 746.51 Million TWD | 2.2% |
| 2008 FY | 730.47 Million TWD | 1.68% |
| 2007 FY | 718.41 Million TWD | 9.83% |
| 2006 FY | 654.09 Million TWD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Grape King Bio Ltd | 6.03 Billion TWD | 75.729% |
| Maywufa Company Ltd. | 854.37 Million TWD | -71.568% |
| ScinoPharm Taiwan, Ltd. | 901.49 Million TWD | -62.599% |
| Lotus Pharmaceutical Co., Ltd. | 4.48 Billion TWD | 67.287% |
| LIWANLI Innovation Co., Ltd. | 54.86 Million TWD | -2571.647% |
| YungShin Global Holding Corporation | 2.04 Billion TWD | 28.416% |
| PhytoHealth Corporation | 67.64 Million TWD | -2067.003% |
| SCI Pharmtech, Inc. | 190.02 Million TWD | -671.394% |
| Formosa Laboratories, Inc. | 1.24 Billion TWD | -17.421% |
| PharmaEssentia Corporation | 4.49 Billion TWD | 67.39% |
| Bora Pharmaceuticals Co., LTD. | 1.74 Billion TWD | 15.859% |